A detailed history of Russell Investments Group, Ltd. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 4,783 shares of ABUS stock, worth $17,362. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,783
Previous 3,464 38.08%
Holding current value
$17,362
Previous $10,000 80.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.12 - $4.56 $4,115 - $6,014
1,319 Added 38.08%
4,783 $18,000
Q2 2024

Aug 08, 2024

BUY
$2.52 - $3.63 $801 - $1,154
318 Added 10.11%
3,464 $10,000
Q1 2024

May 08, 2024

BUY
$2.26 - $2.92 $1,995 - $2,578
883 Added 39.02%
3,146 $8,000
Q4 2023

Feb 05, 2024

SELL
$1.69 - $2.54 $3,109 - $4,673
-1,840 Reduced 44.85%
2,263 $5,000
Q3 2023

Nov 13, 2023

BUY
$1.9 - $2.27 $7,497 - $8,957
3,946 Added 2513.38%
4,103 $8,000
Q2 2023

Aug 10, 2023

SELL
$2.24 - $3.06 $2,658 - $3,632
-1,187 Reduced 88.32%
157 $0
Q1 2023

May 09, 2023

BUY
$2.23 - $3.1 $2,997 - $4,166
1,344 New
1,344 $4,000
Q2 2022

Jul 29, 2022

SELL
$1.98 - $3.17 $8,157 - $13,060
-4,120 Closed
0 $0
Q4 2021

Jan 21, 2022

SELL
$3.11 - $4.61 $13,444 - $19,929
-4,323 Reduced 51.2%
4,120 $16,000
Q3 2021

Nov 08, 2021

SELL
$2.65 - $4.62 $12,227 - $21,316
-4,614 Reduced 35.34%
8,443 $36,000
Q2 2021

Aug 04, 2021

BUY
$2.5 - $3.51 $32,642 - $45,830
13,057 New
13,057 $39,000
Q3 2020

Nov 09, 2020

SELL
$1.75 - $6.2 $75,425 - $267,220
-43,100 Closed
0 $0
Q2 2020

Aug 05, 2020

BUY
$0.91 - $2.36 $39,221 - $101,716
43,100 New
43,100 $78,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $544M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.